Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

Inclusion Criteria:

1. Subject must be able to read, understand and sign informed consent form.

2. Healthy females, 19 and older

3. Fitzpatrick I-VI

4. Has melasma

5. Willing to have RF microneedling treatment and able to adhere to treatments, followup schedule, and post-treatment instructions

6. Willing to have limited sun exposure and use sunscreen on treatment area everydayfor duration of study

7. Willing to have photographs taken of treatment area and agree to use of photographs

8. Willing to refrain from using topical corticosteroids, or retinoids

9. Agree to undergo procedure in treatment area during study

10. Females: not pregnant, or lactating and is either post-menopausal, surgicallysterilized, or using birth control at least 1 month prior to enrollment

11. Willing to wear sunscreen and apply once daily in morning and every 2 hours

Exclusion Criteria:

1. Participation in a clinical trial of another drug, or device administered to thetreatment area, within 3 months prior to enrollment or during the study.

2. Any type of prior cosmetic treatment to the target area within 3 months of studyparticipation, such as laser/light procedures, and those used for general aestheticcorrection, neuromodulators, facial peel, lightening creams, or facial surgery.

3. Any fillers within 3 months prior to enrollment or during the study.

4. Use of prescription topicals in the treatment area within one month prior totreatment or use of topical agents one week prior to treatment that may cause facialsensitivity.

5. Suffering from significant skin conditions in the treated areas or inflammatory skinconditions, including but not limited to, open lacerations or abrasions,hidradenitis, rash, infection, or dermatitis of the treatment area prior totreatment (duration of resolution as per the Investigator's discretion).

6. . Pregnant and/or breastfeeding or planning to become pregnant.

7. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immunedeficiency disorders (including HIV infection or AIDS) or using immunosuppressivemedication.

8. Any use of any medication that is known to increase sensitivity to light orhypersensitivity to light exposure according to the Investigator's discretion.

9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or proneto bruising.

10. If you have a history of squamous cell carcinoma or melanoma in the treatment area,this includes basal cell carcinoma unless: basal cell carcinoma was treated orexcised with no evidence of reoccurrence within the past 6 months prior toscreening. Squamous cell carcinoma in situ, which has been treated or excisedwithout evidence or reoccurrence within the past 6 months prior to screening.

11. . History of epidermal or dermal disorders (particularly if involving collagen ormicro vascularity), including collagen vascular disease or vasculitis disorders.

12. A history or active skin condition that in the opinion of the Investigator mayinterfere/confound with the treatment.

13. History of connective tissue disease, such as systemic lupus erythematosus orscleroderma. Sponsor: VIOL Version 1, 25APR2022 Protocol: VIOL-MEL-2022 Page 18 of 47

14. History of disease stimulated by heat, such as recurrent herpes simplex and/orherpes zoster (shingles) in the treatment area, unless treatment is conductedfollowing a prophylactic regimen.

15. Excessively tanned or active sun tan in facial area to be treated, orunable/unlikely to refrain from tanning during the study.

16. Excessive facial hair in the area to be treated (beards, sideburns, and/ormustache,) that would interfere with diagnosis, assessment, and treatment.

17. As per the Investigator's discretion, any physical or mental condition which mightmake it unsafe for the subject to participate in this study, including excessivealcohol or drug abuses, or a condition that would compromise the subject's abilityto comply with the study requirements.

18. To reduce potential effects of hormonal changes in melasma, a 6-month washout periodis required for female subjects who have recently stopped or started contraceptiveuse, have recently delivered an infant, or have stopped breastfeeding.